首頁
DUSA Pharmaceuticals, Inc.

11月 2025DUSA Pharmaceuticals, Inc.的市場佔有率分析

LEVULAN® KERASTICK® (aminolevulinic acid HCl) + BLU-U® Treatment for minimally to moderately thick actinic keratosis. Please see full Prescribing Information and Instructions for Use.

健康 > 生物技術和製藥

域名dusapharma.com

成立年份1991

僱員51 - 200

年度營收$10M - $15M

DUSA Pharmaceuticals, Inc.

DUSA Pharmaceuticals, Inc.（包含公司地區）

dusapharma.com

查看更多網站流量與參與度資訊

DUSA Pharmaceuticals, Inc.截至 11月 2025 的總收入為 10M - 15M

DUSA Pharmaceuticals, Inc. 熱門網域產生的總收入

DUSA Pharmaceuticals, Inc. 熱門網域 3 年內的總收入

DUSA Pharmaceuticals, Inc. 熱門網域的總收入

dusapharma.com10M - 15M

透過銷售情報查看更多內容

DUSA Pharmaceuticals, Inc.的熱門網域總造訪量

了解DUSA Pharmaceuticals, Inc.市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

無可顯示數據

DUSA Pharmaceuticals, Inc.的熱門網域平均造訪時長

分析DUSA Pharmaceuticals, Inc.參與度指標。

過去 3 個月平均造訪時長

無可顯示數據

DUSA Pharmaceuticals, Inc.的熱門網域平均頁面瀏覽量

了解DUSA Pharmaceuticals, Inc.如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

無可顯示數據

DUSA Pharmaceuticals, Inc.按網域劃分的熱門競爭對手

11月 2025的熱門類似網站，依相似度排名

canderm.com公司名Canderm Pharma inc僱員51 - 200總部加拿大, Montreal年度營收--訪問總量--健康 > 生物技術和製藥

使用的熱門技術DUSA Pharmaceuticals, Inc.

这些是DUSA Pharmaceuticals, Inc.顶级域名使用的行业网站技术

付費廣告 (3)

Facebook Custom Audiences

行動裝置 (3)

Meta Viewport

音訊視訊媒體 (2)

Flowplayer

轉換與分析 (2)

Google Analytics

更多技術

5

檢視所有

新聞與訊號來自DUSA Pharmaceuticals, Inc.

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Dusapharma files suit against Biofrontera AG.We refer to your query, a copy of which is attached herewith, vide your email dated today, July 12, 2018 seeking clarification on announcement submitted by us to the Exchange dated July 11, 2018, regarding SUNPHARMA: Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 11, 2018, titled "DUSA Pharmaceuticals, Inc. files lawsuit against Biofrontera Inc. for patent infringement, trade secret misappropriation, and tortious interference" Response: DUSA Pharmaceuticals, Inc (DUSA), our indirect wholly owned subsidiary company has requested the Court to assess the matter for infringement and to then decide the damages to be granted to DUSA.